Pfizer Inc. (PFE)
| Market Cap | 143.37B |
| Revenue (ttm) | 58.50B |
| Net Income (ttm) | 2.12B |
| Shares Out | 5.65B |
| EPS (ttm) | 0.37 |
| PE Ratio | 68.62 |
| Forward PE | 11.29 |
| Dividend | $1.68 (6.62%) |
| Ex-Dividend Date | Jan 25, 2024 |
| Volume | 31,404,880 |
| Open | 25.35 |
| Previous Close | 25.42 |
| Day's Range | 25.23 - 25.46 |
| 52-Week Range | 25.23 - 40.37 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 36.88 (+45.25%) |
| Earnings Date | May 1, 2024 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $36.88, which is an increase of 45.25% from the latest price.
News
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Pfizer's 15-month fall: Will the stock ever recover?
Pfizer Inc (NYSE:PFE) has been one of the worst-performing large-cap stocks over the last two years. The decline in the stock has been particularly painful for long-term holders as the stock has kept ...
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. ...
RSV Vaccine Could Protect High-Risk Adults Under 60, Pfizer Says
A late-stage trial of Pfizer's RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to...
Pfizer RSV shot meets goals in trial of high-risk adults under age 60
Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adul...
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiO...
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the U.S. Food and Drug Administration...
Redditors Discuss What The Top 3 Value Stock Picks Are Right Now - Pfizer (NYSE:PFE), Taiwan Semiconductor (NYSE:TSM)
In the dynamic world of investing, uncovering value amidst market fluctuations is a quest pursued by many. Reddit's r/ValueInvesting community provides a unique platform where investors converge to sh...
Final Trades: Pfizer, Alphabet and Amazon
The Investment Committee gives you their top stocks to watch for the second half.
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.
After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs.
Final Trades: IBIT, ULTA, LNC & PFE
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
BetterInvesting™ Magazine Update on Paychex Inc. and Pfizer Inc.
TROY, Mich. , March 28, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Paychex Inc. (NYSE: PAYX) as its "Stock to Study" and Pf...
Calls of the Day: Bank of America, Oracle, Abbvie and Pfizer
The Investment Committee debates the latest calls of the day and how to trade them.
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, M...
Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale
Pfizer is raising around $4.27 billion from the sale of part of its stake in consumer-healthcare business Haleon.
Consumer healthcare giant Haleon says Pfizer to cut stake to 24%
Consumer healthcare giant Haleon said on Monday that Pfizer will sell about 630 million of its shares in the company, reducing the US drugmaker's stake to about 24%.
This overlooked corner of women's health could be a $350 billion market opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company's 20-valent pneumococcal conjugate vaccine, mar...
Final Trades: Pfizer, D.R. Horton, Progressive and Alphabet
The Investment Committee shares their top stocks to watch for the second half.
What To Know About Adcetris—Pfizer's Cancer Drug Extended Survival For Patients With Common Lymphoma
Pfizer's cancer drug Adcetris extended survival in patients with a common form of lymphoma in a late-stage trial, the company announced Tuesday, supporting Pfizer's efforts to expand into cancer treat...
Pfizer's drug meets main goal in late-stage blood cancer trial
Pfizer said on Tuesday a combination treatment using its drug, Adcetris, met its main goal of overall survival when tested in patients with a type of blood cancer.
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NEW YORK--(BUSINESS WIRE)--Adcetris Ph3 TLR.